Profile change history

What changed for Survodutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Survodutide identity.

23Total events
18Record additions
5Version changes
2Cited source years

Source-published notices

Research integrity notices

Method and complete cohort →

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT06077864

ClinicalTrials.gov posted a newer version of NCT06077864, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.

Cited source date

Before
2026-08-11
After
2026-11-12

Source observed date

Before
2026-08-13
After
2026-11-15

Cited source records

Before
ctg-observation-nct06077864-2026-08-11-60e24ca2b385
After
ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

Headline citations

Before
ctg-observation-nct06077864-2026-08-11-60e24ca2b385
After
ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

Summary citations

Before
ctg-observation-nct06077864-2026-08-11-60e24ca2b385
After
ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]

Source snapshot commitment

Before
cf0165e7cc8a3abc8cc26353705836f72e2bfabb44e7e332c3453a3a99edeb3c
After
3b3fb4081c8a9faa0e6e6127299a5f54102ba28b220051200879395de0ee0e7d
Record updated

ClinicalTrials.gov record NCT06632457

ClinicalTrials.gov posted a newer version of NCT06632457, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.

Cited source date

Before
2026-08-10
After
2026-11-12

Source observed date

Before
2026-08-13
After
2026-11-15

Cited source records

Before
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
After
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

Headline citations

Before
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
After
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

Summary citations

Before
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
After
ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]

Source snapshot commitment

Before
aa1782b5fe9710da04e66dfed333b0e6510ab67318e432efc980280dfbb568c7
After
36f98358c193a495d298a3a8445a8c403e3a74d6c2d792f4e84ed267e6736dfc
Record updated

ClinicalTrials.gov record NCT07754461

ClinicalTrials.gov posted a newer version of NCT07754461, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.

Cited source date

Before
2026-08-10
After
2026-11-13

Source observed date

Before
2026-08-13
After
2026-11-15

Cited source records

Before
ctg-observation-nct07754461-2026-08-10-d71d6065261a
After
ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

Headline citations

Before
ctg-observation-nct07754461-2026-08-10-d71d6065261a
After
ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

Summary citations

Before
ctg-observation-nct07754461-2026-08-10-d71d6065261a
After
ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]

Source snapshot commitment

Before
b25f4b8af47d59c50496bb719a2c3a947d387fcfbb4510d57581439523e347d9
After
7ee0a3130e4e3b5a7e1ab7330f46659e395d21c4aa5ceb3790c632874e57efef
Profile status changed

Survodutide profile

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
After
An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.

Evidence note

Before
ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.
After
Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.

Cited source records

Before
ctg-nct05202353-v50
After
ctg-nct05202353-v50, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-38330987, journal-pmid-38847460, journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, ctg-observation-nct06632444-2026-08-10-1ea3a43e551b, ctg-observation-nct07754461-2026-08-10-d71d6065261a

Named organizations

Before
Boehringer Ingelheim [sources: ctg-nct05202353-v50]
After
Boehringer Ingelheim [sources: ctg-nct05202353-v50]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

Claim citations

Before
name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50; summary: ctg-nct05202353-v50; evidenceNote: ctg-nct05202353-v50
After
name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50, ctg-observation-nct07754461-2026-08-10-d71d6065261a, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct05202353-v50, journal-pmid-38330987, journal-pmid-42253238, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, fda-unapproved-glp1-concerns-2026-r2
Profile updated

Survodutide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A glucagon/GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.
After
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.

Collection chronology

Evidence added to PeptideScanner

Browse all 18 connected records →

Showing the latest 18 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.

Record added

ClinicalTrials.gov record NCT07940244

PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07221591

PeptideScanner retained ClinicalTrials.gov record NCT07221591 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 27, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07768813

PeptideScanner retained ClinicalTrials.gov record NCT07768813 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07850050

PeptideScanner retained ClinicalTrials.gov record NCT07850050 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07850063

PeptideScanner retained ClinicalTrials.gov record NCT07850063 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07855900

PeptideScanner retained ClinicalTrials.gov record NCT07855900 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 27, 2026
Evidence lane
Clinical trials
Record added

Interpreting Survodutide Renoprotection in a Hyperfiltration Model.

PubMed lists PMID 42897119 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2026-10-19 (day precision). PeptideScanner associated the retained record with the identity slug survodutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 19, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT07413913

PeptideScanner retained ClinicalTrials.gov record NCT07413913 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
September 9, 2026
Cited source date
June 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06077864

PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07754461

PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06632444

PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 13, 2026
Cited source date
August 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06632457

PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 13, 2026
Cited source date
August 10, 2026
Evidence lane
Clinical trials
Record added

PubMed record PMID 40557206

PeptideScanner retained PubMed bibliographic metadata for PMID 40557206 at 2026-07-30T18:26:54.791Z. PubMed recorded a metadata revision date of 2025-06-25 and an Entrez history date of 2025-06-25. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
June 25, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 41388343

PeptideScanner retained PubMed bibliographic metadata for PMID 41388343 at 2026-07-30T16:25:14.127Z. PubMed recorded a metadata revision date of 2026-02-14 and an Entrez history date of 2025-12-13. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
February 14, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41424209

PeptideScanner retained PubMed bibliographic metadata for PMID 41424209 at 2026-07-30T16:25:14.150Z. PubMed recorded a metadata revision date of 2026-02-10 and an Entrez history date of 2025-12-22. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
February 10, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT06176365

PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 8, 2026
Cited source date
April 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06309992

PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.

PeptideScanner change date
August 8, 2026
Cited source date
April 30, 2026
Evidence lane
Clinical trials